Topic List : Cancer
Tracking cancer growth
Cancer research that once involved years of painstaking work can now happen in months with a novel technique for studying cancer-related genes. The results reveal how combinations of mutations influence tumor growth.
Predicting success of lung cancer drug
With the help of a new radioactive tracer, doctors can predict with more than 80 percent accuracy how well a widely-used lung cancer drug will combat tumors, according to researchers at Stanford.
Misbehaving cells predict relapse in leukemia
Analyzing individual cancer cells has enabled Stanford researchers to identify the small population of cells that spur relapse in some children with leukemia.
Reducing side effects of a cancer therapy
Stanford scientists created an odd couple: a modified version of an immune-signaling protein and a coordinately modified receptor for this protein. The two bind only to each other, easing an advanced anti-cancer therapy’s side effects.
IPS cells slow tumor growth in mice
Priming the immune system with induced pluripotent stem cells prevented or slowed the development of cancer in mice, Stanford researchers found.
Potential skin cancer treatment
Stanford researchers have learned how basal cell carcinoma evades drug treatment without mutating. The researchers found possible drug targets that may allow for more personalized treatment of this common skin cancer.
'Vaccine’ destroys tumors in mice
Activating T cells in tumors eliminated even distant metastases in mice, Stanford researchers found. Lymphoma patients are being recruited to test the technique in a clinical trial.
Breast cancer mortality drops
Six groups of researchers, including one from Stanford, collaborated to study the effect of advances in breast cancer screening and treatment on mortality rates.
Screen could reveal immunotherapy targets
Stanford scientists have developed a biochemical screen that identifies molecules critical to immunotherapy for a host of diseases, including cancer.
Chemotherapy declines for breast cancer
Chemotherapy use for early stage breast cancer declined from 2013 to 2015, possibly due to a preference for less toxic treatments, according to researchers at Stanford and the University of Michigan.